EAU 2018: Impact of antiplatelet and anticoagulation therapy for patients undergoing HOLEP in terms of hospitalization length and complications rate: A prospective study
For his comparison, a prospective study was performed on a series of 143 consecutive patients who were stratified into control, antiplatelet and anticoagulation therapy groups after undergoing HoLEP. Preoperative, perioperative and postoperative parameters were measured.
Anticoagulation group was statistically different to the control in terms of catheterization time, length of stay and complication rate, all of which exhibited increased rates. This group also expressed significantly higher outcomes when compared to the antiplatelet group in terms of catheterization and length of stay. Patients on anticoagulation therapy have shown significantly higher hemorrhagic complication rates, such as a five-fold increase in Clavien 3 complications.
In conclusion, patients with over anticoagulation had an increased risk for hemorrhagic complications, however were likely to be non-life threatening therefore only increasing length of hospitalization and catherization time. Additionally, patients under antiplatelet therapy do not have an increased risk and this therapy appears to be safe to maintain when undergoing HoLEP.
Speaker: Dr. B. Branchu
Written by: Whitney Zhang, Department of Urology, University of California-Irvine at the 2018 European Association of Urology Meeting EAU18, 16-20 March, 2018 Copenhagen, Denmark